Aerovate Therapeutics Announces Pricing of Upsized Initial Public Offering

BOSTON, June 29, 2021 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced…

Click here to view the original article.